#	Pagina
attuale pagina	/open-h2020/projects/212675/index.html

Opendata, web and dolomites

MCDS-Therapy SIGNED

Repurposing of carbamazepine for treatment of skeletal dysplasia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

MCDS-Therapy project word cloud

Explore the words cloud of the MCDS-Therapy project. It provides you a very rough idea of what is the project "MCDS-Therapy" about.

450 severe encompasses authorization repurposing september children pain diverse therapy burden form candidate characterised disability phenotypes world forms validated drug smes mutant extrapolates extensive renown thereby reticulum chondrocytes endoplasmic approved treatment clinical relatively skeletal synthesis strategy life rare cbz miss mild model collagen marketing dossier disorder er affordable fda countries 225 received people gsds alleviate biomarker epilepsy comprising shown aus bipolar minimum economics individually schmid fold poor stress caused multinational trial healthcare designation repurposed prevalence innovative extremely multicentre prognosis causing molecules health bone population mutations lethal exists skeleton mcds 27 lt carbamazepine retained phase1 group diseases orphan genetic diagnosis phase2 2022 metaphyseal least tools hypertrophic 2016 expression collaborative restore personalise quality centres mouse severity leads chondrodysplasia

Project "MCDS-Therapy" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITY OF NEWCASTLE UPON TYNE Organization address address: KINGS GATE city: NEWCASTLE UPON TYNE postcode: NE1 7RU website: http://www.ncl.ac.uk/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	https://mcds-therapy.eu/
Total cost	5˙697˙390 €
EC max contribution	5˙697˙390 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2017-Two-Stage-RTD
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-12-01 to 2022-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITY OF NEWCASTLE UPON TYNE UNIVERSITY OF NEWCASTLE UPON TYNE Organization address address: KINGS GATE city: NEWCASTLE UPON TYNE postcode: NE1 7RU website: http://www.ncl.ac.uk/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (NEWCASTLE UPON TYNE)	coordinator	2˙175˙161.00
2	ISTITUTO ORTOPEDICO RIZZOLI ISTITUTO ORTOPEDICO RIZZOLI Organization address address: VIA DI BARBIANO 1/10 city: BOLOGNA postcode: 40136 website: www.ior.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (BOLOGNA)	participant	782˙175.00
3	UNIVERSITAETSKLINIKUM FREIBURG UNIVERSITAETSKLINIKUM FREIBURG Organization address address: HUGSTETTER STRASSE 49 city: FREIBURG postcode: 79106 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (FREIBURG)	participant	657˙569.00
4	SCIOMICS GMBH SCIOMICS GMBH Organization address address: SCHNEIDMUHLSTRASSE 19 city: HEIDELBERG postcode: 69115 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HEIDELBERG)	participant	604˙030.00
5	FINOVATIS FINOVATIS Organization address address: COURS LAFAYETTE 68 city: LYON postcode: 69003 website: www.finovatis.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LYON)	participant	320˙937.00
6	MURDOCH CHILDRENS RESEARCH INSTITUTE MURDOCH CHILDRENS RESEARCH INSTITUTE Organization address address: FLEMINGTON ROAD RCH city: PARKVILLE postcode: 3052 website: www.mcri.edu.au contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AU (PARKVILLE)	participant	318˙625.00
7	FINDACURE FOUNDATION FINDACURE FOUNDATION Organization address address: 66 DEVONSHIRE ROAD city: CAMBRIDGE postcode: CB1 2BL website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (CAMBRIDGE)	participant	309˙235.00
8	ASSISTANCE PUBLIQUE HOPITAUX DE PARIS ASSISTANCE PUBLIQUE HOPITAUX DE PARIS Organization address address: 3 AVENUE VICTORIA city: PARIS postcode: 75000 website: http://www.aphp.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	211˙479.00
9	GUYS AND ST THOMAS' NHS FOUNDATIONTRUST GUYS AND ST THOMAS' NHS FOUNDATIONTRUST Organization address address: Westminster Bridge Road city: London postcode: SE1 7EH website: http://www.guysandstthomas.nhs.uk/home.aspx contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (London)	participant	197˙428.00
10	UNIVERSITAIR ZIEKENHUIS ANTWERPEN UNIVERSITAIR ZIEKENHUIS ANTWERPEN Organization address address: WILRIJKSTRAAT 10 city: EDEGEM postcode: 2650 website: www.uza.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (EDEGEM)	participant	120˙750.00

Map

Project objective

Genetic skeletal diseases (GSDs) are an extremely diverse and complex group of rare genetic diseases that affect the development the skeleton. There are more than 450 unique and well-characterised phenotypes that range in severity from relatively mild to severe and lethal forms. Although individually rare, as a group of related genetic skeletal diseases, GSDs have an overall prevalence of at least 1 per 4,000 children, which extrapolates to a minimum of 225,000 people in the 27 member states and candidate countries of the EU. This burden in pain and disability leads to poor quality of life and high healthcare costs. Metaphyseal chondrodysplasia, type Schmid (MCDS) results from mutations in collagen X and affects <1/100,000 of the population. Mutant collagen X molecules miss-fold during synthesis and are retained within the endoplasmic reticulum (ER) of hypertrophic chondrocytes, thereby causing ER stress. Our extensive pre-clinical studies have shown that carbamazepine (CBZ) can alleviate ER stress caused by the expression of mutant collagen X and restore bone growth in a validated mouse model of MCDS. CBZ is an FDA approved drug used for the treatment of epilepsy and bipolar disorder and received orphan drug designation by the European Commission for the treatment of MCDS in September 2016. MCDS-Therapy is a 5-year collaborative project comprising world-renown clinical centres and SMEs to advance the repurposing of CBZ for MCDS (up to the Marketing Authorization Application dossier) through a multicentre and multinational (EU & AUS) clinical trial (Phase1, Phase2/3). MCDS-Therapy also encompasses biomarker development and health economics assessment studies to deliver by 2022 an innovative and affordable (CBZ already exists in a generic form) repurposed therapy for MCDS along with the diagnosis/prognosis tools to personalise the treatment strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MCDS-THERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MCDS-THERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More

HEADSpAcE (2019)

Translational studies of HEAD and neck cancer in South America and Europe

Read More

BETTER-B (2019)

BETTER TREATMENTS FOR BREATHLESSNESS IN PALLIATIVE AND END OF LIFE CARE

Read More